Search research articles
Contact Us
Filters
Showing results (71-80 of 93) with videos related to
Page
of 10
Sort By:
British Journal of Pharmacology
|
January 11, 2003
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex
Matteo Marti, Sara Stocchi, Francesca Paganini, et al.
Brain : a Journal of Neurology
|
April 20, 2021
LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation
Francesca Pischedda, Maria Daniela Cirnaru, Luisa Ponzoni, et al.
Materials Science & Engineering. C, Materials for Biological Applications
|
January 13, 2015
Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity
Laura Ravani, Maria Grazia Sarpietro, Elisabetta Esposito, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 3, 2007
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies
Barbara Spagnolo, Giacomo Carrà, Martina Fantin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 1, 2010
Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease
Matteo Marti, Silvio Sarubbo, Francesco Latini, et al.
British Journal of Pharmacology
|
December 13, 2017
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists
Ludovico Arcuri, Salvatore Novello, Martina Frassineti, et al.
ACS Chemical Neuroscience
|
April 7, 2015
Selectivity and anti-Parkinson's potential of thiadiazolidinone RGS4 inhibitors
Levi L Blazer, Andrew J Storaska, Emily M Jutkiewicz, et al.
Acta Neuropathologica Communications
|
March 16, 2017
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice
Francesco Longo, Daniela Mercatelli, Salvatore Novello, et al.
Neurobiology of Disease
|
December 6, 2021
In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity
Salvatore Novello, Daniela Mercatelli, Federica Albanese, et al.
Scientific Reports
|
April 11, 2017
Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity
Silvia Sacchi, Vito De Novellis, Giovanna Paolone, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 93) with videos related to
Sort By:
Page
of 10
British Journal of Pharmacology
|
January 11, 2003
Pharmacological profiles of presynaptic nociceptin/orphanin FQ receptors modulating 5-hydroxytryptamine and noradrenaline release in the rat neocortex
Matteo Marti, Sara Stocchi, Francesca Paganini, et al.
Brain : a Journal of Neurology
|
April 20, 2021
LRRK2 G2019S kinase activity triggers neurotoxic NSF aggregation
Francesca Pischedda, Maria Daniela Cirnaru, Luisa Ponzoni, et al.
Materials Science & Engineering. C, Materials for Biological Applications
|
January 13, 2015
Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity
Laura Ravani, Maria Grazia Sarpietro, Elisabetta Esposito, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 3, 2007
Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies
Barbara Spagnolo, Giacomo Carrà, Martina Fantin, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 1, 2010
Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease
Matteo Marti, Silvio Sarubbo, Francesco Latini, et al.
British Journal of Pharmacology
|
December 13, 2017
Anti-Parkinsonian and anti-dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists
Ludovico Arcuri, Salvatore Novello, Martina Frassineti, et al.
ACS Chemical Neuroscience
|
April 7, 2015
Selectivity and anti-Parkinson's potential of thiadiazolidinone RGS4 inhibitors
Levi L Blazer, Andrew J Storaska, Emily M Jutkiewicz, et al.
Acta Neuropathologica Communications
|
March 16, 2017
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice
Francesco Longo, Daniela Mercatelli, Salvatore Novello, et al.
Neurobiology of Disease
|
December 6, 2021
In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity
Salvatore Novello, Daniela Mercatelli, Federica Albanese, et al.
Scientific Reports
|
April 11, 2017
Olanzapine, but not clozapine, increases glutamate release in the prefrontal cortex of freely moving mice by inhibiting D-aspartate oxidase activity
Silvia Sacchi, Vito De Novellis, Giovanna Paolone, et al.
Page
of 10